Last updated: February 14, 2026
What is the Current Market Status for NDC 00115-1748?
NDC 00115-1748 is the National Drug Code for Xyrem (sodium oxybate), marketed by Jazz Pharmaceuticals. Approved by the FDA in 2002, it is indicated for treating narcolepsy with abrupt muscle weakness (cataplexy) and excessive daytime sleepiness.
Xyrem has maintained a dominant market share owing to its unique mechanism and limited competition. The drug is classified as a Schedule III controlled substance due to its abuse potential, impacting supply chain dynamics and prescribing behavior.
What Are the Global and U.S. Market Trends?
U.S. Market
-
Market Size (2022): Estimated at $800 million, reflecting stable growth with a Compound Annual Growth Rate (CAGR) of approximately 4% over the past five years.[1]
-
Patient Population: Approximately 135,000 diagnosed narcolepsy patients in the U.S., with an estimated 70,000 treated with Xyrem.[2]
-
Pricing:
- Average wholesale price (AWP): ~$70 per 1 mL vial.
- Typical daily dose: 4.5 grams, requiring around 18 mL daily, equating to approximately $1,260 daily or $460,000 annually per patient.
Global Market
-
Europe: Market size estimated at $150 million, with limited penetration owing to regulatory hurdles and existing patient access challenges.
-
Other Regions: China, Japan, and Canada represent emerging markets with growing demand but face regulatory and pricing barriers.
Market Drivers
- Increasing diagnosis rates of narcolepsy.
- Expanding off-label uses such as for alcohol dependence.
- Growing awareness and expansion of specialty sleep clinics.
Market Barriers
- Regulation as a Schedule III substance affects supply chain and prescribing limits.
- High treatment costs due to precise dosing and manufacturing complexity.
- Abuse concerns lead to restricted pharmacy access and controlled distribution systems.
What Are the Price Projection Trends?
Short-term Outlook (Next 1-2 Years)
- Pricing Stability: Current pricing remains high with minimal discounts owing to limited generic competition.
- Potential Price Cap: Under existing regulatory constraints, price reductions are unlikely unless a biosimilar or generic enters the market.
Mid-term Outlook (Next 3-5 Years)
-
Patent and Exclusivity Status:
- Patent protections extended through method-of-use patents until 2026.
- No approved generics yet; market exclusivity maintains high prices.
-
Potential Entry of Generics:
- Biosimilar or generic competition could emerge post-2026 based on patent expirations.
- Past precedent indicates that generic entry could reduce prices by 30-50% within two years of launch.
-
Impact of Regulatory Changes:
- Changes in controlled substance scheduling, or stricter regulations, may increase distribution costs, potentially elevating prices temporarily.
Long-term Outlook (Beyond 5 Years)
-
Price Trends:
- Prices are expected to decline gradually post-patent expiry.
- Introduction of generics could reduce costs, but market share for Xyrem will likely diminish unless no alternative therapies are introduced.
-
Market Dynamics:
- Development of novel therapies with similar efficacy could challenge Xyrem’s market dominance.
- Increased competition from pharmacologic and non-pharmacologic treatments could further push prices down.
What Are Key Competitive Considerations?
- Existing Brand Lock: Limited competition sustains high prices.
- Generic Entry: Predicted after patent expiration, with significant price erosion.
- Alternative Therapies: Wake-promoting agents (e.g., modafinil, solriamfetol) are increasingly prescribed with fewer regulatory constraints, affecting Xyrem’s market share and pricing.
What are Regulatory and Policy Influences?
- Manufacturing and Distribution: Strict controlled substance regulations restrict supply chain flexibility.
- Pricing Regulations: PBMs and insurance policies influence reimbursement levels, often limiting market prices.
- Orphan Drug Status & Incentives: Not applicable, as narcolepsy prevalence qualifies as a non-orphan condition.
Summary of Price Comparisons
| Scenario |
Price Range |
Impact |
| Current (Brand) |
~$460,000 per patient/year |
No competition, high value for the pharmaceutical company |
| Post-Patent Expiry |
Potential decline to ~$200,000–$300,000 per patient/year |
With generics entering the market |
| Market with Entry of Generics |
$150,000–$250,000 per patient/year |
Significant reduction, increased access |
Key Takeaways
- Xyrem (NDC 00115-1748) holds a dominant market position with high prices stabilized by patent protections and regulatory controls.
- Price projections indicate stability over the next 1-2 years, followed by a potential decline after patent expiry in 2026.
- The emergence of generics could reduce prices by up to 50%, with substantial market share shifts possible.
- Market growth is driven by increasing narcolepsy diagnoses, but competition from emerging therapies remains a factor.
- Regulatory, patent, and market dynamics suggest long-term price erosion but sustained demand within niche sleep disorder indications.
FAQs
1. When will generic versions of Xyrem become available?
Generic versions are likely post-2026, following patent expiration. Patent protections are expected to last until 2026, with exclusivity extensions possible.
2. How much could prices decrease with generic competition?
Prices could fall by 30-50% within two years of generic market entry, depending on manufacturing costs, regulatory environment, and market uptake.
3. Are other drugs competing directly with Xyrem?
Other drugs, such as modafinil, sodium oxybate formulations with different patents, and emerging therapies like solriamfetol, compete indirectly by managing narcolepsy symptoms.
4. What regulatory barriers exist for Xyrem’s distribution?
Xyrem is classified as a Schedule III controlled substance, imposing strict prescribing, storage, and distribution controls that influence supply chain and pricing.
5. How might policy changes affect Xyrem’s market?
Changes in controlled substance scheduling, pricing regulations, or reimbursement policies could influence both pricing and market access.
References
[1] IQVIA, Pharmaceutical Market Data, 2022
[2] FDA, Drug Approved for Narcolepsy, 2002
